CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Gregg Lapointe to its Board of Directors. Mr. Lapointe has three decades of commercial and financial experience and he is Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases.
“Gregg’s broad set of experiences as a leader and a director makes him an excellent addition to our board of directors,” said Ken Bate, co-Chairman of Catabasis’ Board of Directors. “His past roles involving commercial operations and rare diseases will be very valuable as we move through Phase 3 and prepare for a commercial launch of our lead program edasalonexent.”
“I am incredibly excited at the potential for edasalonexent to have a significant impact on the treatment landscape for Duchenne muscular dystrophy, and I look forward to contributing my expertise as Catabasis prepares to bring this novel therapy to all that could benefit,” said Gregg Lapointe.
Mr. Lapointe currently serves on the Board of Directors of Cytori Therapeutics, Inc., Soligenix, Inc., and Rigel Pharmaceuticals, Inc. Prior to founding Cerium Pharmaceuticals, Mr. Lapointe served as Chief Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a private biopharmaceutical company, from 2008 to 2012 as well as Chief Operating Officer from 2003 to 2008. Mr. Lapointe holds a Bachelor of Commerce from Concordia University (Montreal), a graduate diploma in Accountancy from McGill University (Montreal), an MBA from Duke University and is a CPA (Illinois).
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about future clinical trial plans including, among other things, statements about the Company’s global Phase 3 PolarisDMD trial in DMD to evaluate the efficacy and safety of edasalonexent for registration purposes, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.